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Abstract: The first PIVET algorithm for individualized recombinant follicle stimulating hormone 
(rFSH) dosing in in vitro fertilization, reported in 2012, was based on age and antral follicle count 
grading with adjustments for anti-Müllerian hormone level, body mass index, day-2 FSH, and 
smoking history. In 2007, it was enabled by the introduction of a metered rFSH pen allowing small 
dosage increments of ~8.3 IU per click. In 2011, a second rFSH pen was introduced allowing more 
precise dosages of 12.5 IU per click, and both pens with their individual algorithms have been 
applied continuously at our clinic. The objective of this observational study was to validate the 
PIVET algorithms pertaining to the two rFSH pens with the aim of collecting #15 oocytes and 
minimizing the risk of ovarian hyperstimulation syndrome. The data set included 2,822 in vitro 
fertilization stimulations over a 6-year period until April 2014 applying either of the two individual-
ized dosing algorithms and corresponding pens. The main outcome measures were mean oocytes 
retrieved and resultant embryos designated for transfer or cryopreservation permitted calculation 
of oocyte and embryo utilization rates. Ensuing pregnancies were tracked until live births, and live 
birth productivity rates embracing fresh and frozen transfers were calculated. Overall, the results 
showed that mean oocyte numbers were 10.0 for all women ,40 years with 24% requiring rFSH 
dosages ,150 IU. Applying both specific algorithms in our clinic meant that the starting dose was 
not altered for 79.1% of patients and for 30.1% of those receiving the very lowest rFSH dosages 
(#75 IU). Only 0.3% patients were diagnosed with severe ovarian hyperstimulation syndrome, all 
deemed avoidable due to definable breaches from the protocols. The live birth productivity rates 
exceeded 50% for women ,35 years and was 33.2% for the group aged 35–39 years. Routine use 
of both algorithms led to only 11.6% of women generating .15 oocytes, significantly lower than 
recently published data applying conventional dosages (38.2%; P,0.0001). When comparing both 
specific algorithms to each other, the outcomes were mainly comparable for pregnancy, live birth, 
and miscarriage rate. However, there were significant differences in relation to number of oocytes 
retrieved, but the mean for both the algorithms remained well below 15 oocytes. Consequently, 
application of both these algorithms in our in vitro fertilization clinic allows the use of both the 
rFSH products, with very similar results, and they can be considered validated on the basis of 
effectiveness and safety, clearly avoiding ovarian hyperstimulation syndrome.
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Introduction
The first live births from in vitro fertilization (IVF) were achieved from single oocytes 
recovered from monitoring natural cycles and detecting the luteinizing hormone surge. 
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However, higher rates of pregnancy and live births were 
found after ovarian stimulation followed by human chorionic 
gonadotrophin (HCG) trigger to recover several oocytes in 
a controlled fashion. Currently, ovarian stimulation is most 
often undertaken with recombinant follicle stimulating hor-
mone (rFSH), and the starting dose of this gonadotrophin is 
important for achieving optimal numbers of oocytes in order 
to produce viable embryos. However, the response needs to 
be tempered to diminish the risk of ovarian hyperstimulation 
syndrome (OHSS), a potentially lethal condition, occurring 
at increased likelihood when oocyte numbers exceed 15. 
At present, most clinicians still rely on a standard dose of 
rFSH, typically 150–225 IU, with adjustments based on each 
clinician’s experience and the patient’s previous response. 
The earliest attempts to develop algorithms based on vari-
ous biological and anthropometric parameters ensued from 
an academic IVF group in Copenhagen1,2 who constructed 
their risk algorithm based on antral follicle count (AFC), 
ovarian volume, Doppler score, age, and smoking habits. 
However, some of these parameters are not commonly used, 
measured, or not obtainable in most clinics. Howles et al3 
evaluated several potential variables and identified four 
critically important parameters: FSH level at screening, body 
mass index (BMI), age, and number of follicles ,11 mm and 
found them to be the most predictive factors. A formula was 
calculated using the CONSORT algorithm based on these 
four variables. This algorithm was tested in a multicentre 
study on 172 normoovulatory women aged 18–34 years, and 
a mean of 10.3 oocytes was retrieved. However, the cancel-
lation rate was as much as 17%, which was rather high in 
this potentially good-responder group.4
Recently, PIVET Medical Centre published an algorithm5 
designed to calculate the appropriate dosage of rFSH to 
provide 8–12 oocytes from all women within the IVF pro-
gram and to reduce the risk of severe OHSS. The algorithm 
covered all patients from very poor responders to hyper-
responders. The rationale behind that algorithm was to target 
those women at higher risk for OHSS with smaller dosages 
of rFSH than was standard practice. This was enabled by the 
introduction of the Puregon Pen by Merck Sharp & Dohme 
(Sydney, NSW, Australia) (MSD) into Australia in 2007, 
which enabled a dial-up dosage of 25 IU increments, but 
with three subdivisional clicks assumed to be approximately 
8.3 IU each (Figure 1). This algorithm then allowed much 
lower dosages to be provided to women with high AFC rat-
ings and higher anti-Müllerian hormone (AMH) levels, and 
the dose was adjusted downwards for younger women and 
those with low BMI ratings.
The original PIVET algorithm enabled rFSH dosages for 
the Puregon Pen,5 which were much lower than the usually 
administered 150–225 IU, yet still permitted an adequate 
response but with minimal risk of over-response and the 
associated concomitant risk of severe OHSS. According to the 
algorithm, such dosage could range as low as 41.7 IU daily 
for very young women with BMI as low as 16 kg/m2, often 
with typically enlarged polycystic ovaries and AMH levels 
.30 pmol/L. Such women had “targeted mild stimulation” 
but still had the benefits of sufficient oocytes to enable blasto-
cyst culture and single embryo transfers (ETs) as well as the 
benefit of some embryos for cryopreservation facilitating a 
higher pregnancy productivity rate6 from a single transvaginal 
oocyte aspiration (TVOA). From our perspective, this strategy 
is superior to the idea of minimal stimulation protocols using 
clomiphene citrate, where few eggs are recovered, many cases 
are cancelled, and minimal cases have the benefit of additional 
cryopreserved embryos for future use.7
At the time of the algorithm study (October 2009), only 
the Puregon Pen enabled small dosage increments (~8.3 IU), 
while the competitive Gonal-f Pen (Merck Serono, Sydney, 
Australia) allowed only 37.5 IU increments, which in our 
pilot studies proved to be unsatisfactory in achieving our 
aims. Subsequently, Merck Serono introduced a new pen 
early in 2011, which enabled three clicks between the previ-
ous dosages, that is, increments of 12.5 IU/click and filled by 
mass so that rFSH quantity was assured. We elected to design 
two new algorithms, one adjusted to 12.5 increments for the 
Gonal-f Pen (Figure 2), and a revised version of the original 
Puregon algorithm (Figure 1), that captures the current trend 
in a reduction of maximal rFSH dosages from 600 to 450 IU5, 
thus providing clinicians with the option to use either of the 
rFSH products with a view to targeted low-dose stimulation 
of those women at increased risk of OHSS.
The current observational study analysed IVF data 
following stimulation using either PIVET algorithms, and 
adjusted for 8.3 IU or 12.5 IU increments over a continu-
ous 6-year period. The clinical aims were to collect eight to 
twelve oocytes for optimal benefit and four to eight oocytes 
in the very-high-risk group, while maintaining a minimum 
risk of overstimulation. These data showed that routine 
application of the PIVET algorithms respective for each drug 
makes these aims eminently feasible.
Materials and methods
study design
This retrospective study covers a continuous 6-year period at 
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PiVeT rFsh dosing algorithms for iVF
the algorithms were used to determine the rFSH starting dose. 
The data were drawn from our entire database containing all 
cases treated in this 6-year period (Figure 3). The data period 
enabled all pregnancies to be tracked through to deliveries. 
Few patients with BMI .36 kg/m2 were treated during the 
entire period, and they were treated according to the algo-
rithms as if the BMI was 35 kg/m2. The protocol was the same 
as applied in our previous publication,5 but the new algorithm 
for Gonal-f was introduced in April 2011 with the launch 
of the new pen. Dosages were adjusted to be close to the 
original Puregon dosages, and both the rFSH products were 
used routinely based on clinicians’ choice and availability in 
the current study. All clinical and laboratory management of 
IVF or Intracytoplasmic Sperm Injection (ICSI) procedures 
was not altered during the entire 6-year study period, apart 
from trends in ETs, namely more cases committed to blasto-
cyst culture, more single ETs, and more cases with selective 
cryopreservation of the better quality embryos.
Patient management
All IVF patients completed informed and written consent 
when undergoing an assessment cycle, which occurred fol-
lowing their primary consultation and within 1–2 months 
immediately prior to the IVF treatment cycle. This included 
serum day-2 FSH, AMH, and AFC measured day 5±1 along 
with cycle tracking, a hysterosalpingo-contrast-sonography 
(HyCoSy) test day 7 to day 9, periovulatory postcoital 
evaluation, and mid-luteal serum progesterone (P4). At this 
latter, mid-luteal point, the couple were reviewed for the 
consideration of treatment proposals. For those proceeding 
to IVF, the clinician decided the stimulation protocol, and 
the starting gonadotrophin dosage was calculated from the 
appropriate algorithm. However, if a further fresh cycle was 
planned, the essential measurement parameters were repeated 
in the month prior to the cycle and the rFSH dosage calculated 
at the day 21 pre-IVF check. Clinicians were instructed to 
avoid adjusting dosages on the basis of previous responses 
Figure 3 Derivation of 2,822 cases of iVF initiated over a 6-year period at PiVeT Medical centre applying PiVeT algorithms.
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(eg, oocytes collected) but to simply calculate using the 
updated parameters.
PiVeT algorithm development
Examination of more than 5,000 IVF cycles along with 
tracking the destiny of more than 50,000 recovered oocytes 
created a profile of those protocols leading to the develop-
ment of eight to twelve follicles and oocytes according to 
the background AFC ratings. These data were then compared 
with the risk charts (chance of pregnancy vs risk of OHSS) 
published from the Copenhagen Group.1,2 As the algorithms 
evolved, we applied data modeling and graphic smoothing 
techniques to create a continuously rising dosage schedule, 
without irregularity. As previously stated, we commenced 
by applying the Puregon Pen, which is filled by bioassay and 
provides MSD-guaranteed dosages of 25 IU rFSH. We made 
an assumption that each click of the pen provides approxi-
mately one-third dosage, that is, ~8.3 IU/click, although this 
has not been endorsed or confirmed by MSD, hence ~8.3 IU 
increments (Figure 1).5 Following the release of the Gonal-f 
Pen (Merck Serono) in 2011, we applied the closest dosage 
schedule to match the Puregon Pen algorithm, with further 
data modeling and graphic smoothing techniques to create 
the model, as shown in Figure 2. Merck Serono indicates that 
it is this rFSH pen that is filled by mass; hence, all dosage 
increments of 12.5 IU are fully endorsed and quality assured 
by Merck Serono.
selecting rFsh and adjusting starting 
dosage
The main parameters relevant to the algorithm are female, 
age, and current AFC rating, where all detectable follicles 
2–10 mm are included. Definition of ratings are grade E, #4 
follicles; grade D, 5–8 follicles; grade C, 9–12 follicles; 
grade B, 13–19 follicles; and grade A, 20–29 follicles 
(Figure 3). Patients in the latter grade belong to the high-
risk polycystic ovary group and are further classified as 
grade A+ (30–39 follicles) and grade A++ ($40 follicles) 
Figure 3. In selecting the AFC grading, the AMH level was 
also factored in as a modulator, adjusting the AFC grading 
category upwards if AMH implied a higher AFC rating (eg, 
if the AFC categorized to B, but AMH categorized to A, 
the patients would be categorized as an A grading). Clini-
cians are advised not to adjust the AFC rating downwards if 
suggested by a lower AMH reading as this implies a higher 
rFSH dosage, often proving inappropriate with excessive 
ovarian responses. Internal correlation studies at PIVET 
show high correlation between AMH and AFC, but there can 
be discordance in ~11% of cases (Keane et al; unpublished 
data, 2016). Moving the AFC rating upwards ensured that 
a lower dosage of rFSH would be selected, ensuring safety 
and reducing risk of overstimulation and OHSS. The cur-
rent AMH levels were determined using Gen II (Beckman 
Coulter, Brea, CA, USA).8 Other adjustments within the 
algorithm include BMI, smoking history, and day-2 serum 
FSH, the latter adjusting 1 or 2 readings to the right (ie, 
higher rFSH dosage; Figure 1). Patients classified as egg 
donors or those having egg storage (freeze all) have their 
rFSH dosage adjusted four readings to the right (ie, higher 
rFSH dosage), as they will have an antagonist stimulation 
cycle with agonist (eg, Lucrin, leuprolide acetate; Abbott 
Australasia Pharmaceuticals, Sydney, NSW, Australia) trig-
ger9 and no luteal support drugs because there is no transfer 
and the risk of OHSS is considered to be low. These data have 
been included to determine the impact of the algorithms on 
oocyte retrieval and utilization but excluded for calculations 
of pregnancy, live births, and miscarriage rates.
Ovarian stimulation regimens
Women with high AFC ratings (all A categories and some 
B if AFC .15 antral follicles) were treated by an antagonist 
regimen preferentially. Those with low categories (D and E) 
were treated by a flare regimen with some very poor respond-
ers treated by an agonist antagonist conversion with estrogen 
priming (AACEP) regimen.10 Women with AFC category 
B ,15 antral follicles and category C could be treated by 
either regimen or even a long downregulation protocol at 
clinician’s discretion. The long down-regulation protocol 
was also preferred for cases of underlying adenomyosis 
and endometriosis. This approach accords with the Nelson 
algorithm.11
adjusting rFsh dosage
IVF cycle management commences with day-2 parameters of 
estradiol (E2) ,200 pmol/L, P4 ,5.0 nmol/L, and luteinizing 
hormone ,10 IU/L. FSH levels are measured and may lead to 
adjustment of the algorithm dosage if different from previous, 
for example, FSH 20 IU may cause rFSH dosage selection 2 
squares to the right (8.3/12.5 to 16.7/25 IU where ,300 IU; 
or 25–37.5 IU where $300 IU). Most cycles utilize the 
antagonist regimen, with rFSH commencing on day 3, but 
“agonist flare cycles” means that patients commence Lucrin 
4 IU on day 2, followed by rFSH day 3. Serum E2 levels 
are determined at day 7, and if .500 pmol/L, the dosage 
of rFSH remains unchanged. Conversely, lower levels will 
require 12.5 IU incremental rises in dosage. The antagonist 
(Orgalutran: MSD or Cetrotide; Merck Serono) 0.25 mg is 
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PiVeT rFsh dosing algorithms for iVF
and luteinizing hormone levels are measured every 2–3 days 
along with follicle tracking by transvaginal ultrasound from 
day 9. Most cases present with two or more leading fol-
licles, .17 or ($18) mm on day 12 of the cycle, the most 
common day for giving the ovulatory trigger, and TVOA is 
scheduled for 37 hours posttrigger.
Trigger and luteal support
Recombinant HCG (rhCG: Ovidrel; Merck Serono) was 
used as ovulation trigger in doses 6,500–13,000 IU (one or 
two ampoules). However, in cases considered at high risk 
of developing OHSS ($12 follicles or $12,000 pmol/L E2) 
and treated with an antagonist regimen, GnRHa (leuprolide 
acetate, Lucrin 50 IU; Abbott Australasia Pharmaceuticals, 
Sydney, NSW, Australia) was used as the ovulatory trigger. 
Luteal support was given as described earlier5 and includes 
rhCG 500–1,000 IU days 4, 7, 10, and 13 after TVOA for 
those cases with ,12 follicles and ,12 oocytes according 
to our long-standing practices;12,13 all other cases received 
P4 400 mg thrice daily. Cases with .12 oocytes were given 
Cabergoline 1 mg nocte for 10 days and cases .20 oocytes 
had freeze-all except if the trigger was Lucrin.
intensive monitoring protocol
Women were classified as OHSS risk at two occasions – 
firstly, at trigger if E2 was $12,000 pmol/L or ultrasound 
revealed $12 follicles that were $12 mm; and secondly, at 
TVOA if $12 oocytes were recovered. Such patients were 
instructed to record abdominal girth at the umbilicus each day 
and report the measurement and wellness (especially noting 
breathing difficulty, urine flow, and color, as well as any nau-
sea and/or vomiting) daily to the clinic nurse. A blood test was 
performed every third day and was considered for E2 .6,000 
pmol/L or P4 .600 nmol/L; such cases having luteal phase 
support adjusted to exclude rhCG, if previously prescribed. 
Women exceeding safe parameters were arranged for abdomi-
nal ultrasound to check for OHSS (and need for paracentesis), 
along with urine sample to detect specific gravity (SG) and 
need for intravenous hydration if SG .1,015.
eT trends
In the late algorithm period, there were some changing trends 
in ET policies. Overall, there was a strong Australian drive 
to minimize multiple pregnancies; hence, elective single 
ETs were encouraged. There was also a concern that those 
cycles characterized by rising P4 levels prior to trigger 
would result in disturbances affecting embryo–endometrial 
synchrony, therefore PIVET policy changes encouraged 
cryopreservation by vitrification of the best-quality embryos, 
and fresh transfer of those embryos graded in the lower tier. 
The trend also included an increased blastocyst culture policy. 
Consequently, fewer embryos became available for transfer 
or cryopreservation.
Oocyte retrieval and pregnancy 
outcomes
Two utilization measures were calculated to summate the 
proportion of “usable” embryos transferred or vitrified arising 
from the total number of two pronucleate embryos generated 
from a single oocyte retrieval procedure (embryo utilization 
rate), or the proportion of “usable” oocytes transferred and 
vitrified arising from the total number of oocytes retrieved 
from a single oocyte retrieval procedure (oocyte utilization 
rate). The outcomes of treatment cycles are categorized 
for cycles initiated and fresh cycles per TVOA or per ET. 
They are categorized as clinical pregnancy rate (detectable 
foetal heartbeat at 7 weeks) or live birth rate (at least one 
live, surviving infant after 28 weeks). The pregnancy and 
live birth productivity rates include the subsequent frozen 
embryo transfer outcomes arising from the single TVOA 
procedure from an individual IVF treatment cycle. PIVET 
introduced this terminology to avoid confusion with the 
term “cumulative pregnancy rate,” which mostly relates to 
outcomes from more than one IVF treatment cycle.5,6 By 
using productivity rates, the outcomes of IVF treatments, 
where top-quality embryos are frozen for various reasons, for 
example, elevated late follicular P4 levels or risk of OHSS, 
can still be favorably reflected.14
statistical analysis
Data were analyzed using Prism 6 (GraphPad Software, Inc., 
La Jolla, CA, USA) applying one-way or two-way analysis 
of variance for multiple comparisons of the means within 
groups, including AFC and age groupings. Ratios were 
compared using χ2 contingency tables applying Fisher’s 
exact test. P-values ,0.05 were considered statistically sig-
nificant. Multivariate statistical analysis was conducted by 
logistic regression using SPSS version 22 (IBM Corporation, 
Armonk, NY, USA).
Results
A summary of treatment cycle details along with patient 
age distribution is shown in Table 1. The mean age for the 
total women treated during the 73-month study period was 
36.2 years, and ages ranged from 20 to 51 years. The most 
commonly applied stimulation protocols were the antagonist 
regimen (57.4% of cases) followed by the flare protocol 
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were treated by other protocols including the long agonist 
downregulation protocol and the variant AACEP regimen. 
The incidence of women needing admission to hospital for 
various diagnoses post-TVOA is shown in Table 1. In order 
to track all patients developing OHSS, 483 risk patients had 
the intensive monitoring protocol (IMP) applied during the 
period. Furthermore, 308 patients with .12 oocytes were 
treated with Cabergoline to diminish or prevent OHSS symp-
toms. Nine cases were categorized as severe OHSS requiring 
paracentesis or drainage of pleural effusion (one case), which 
comprised 0.3% of all cases receiving rFSH stimulation. 
Only one case of severe OHSS occurred during the reporting 
period of the first algorithm publication5 and that related to a 
marked violation of protocol. In this full study period, each of 
the nine cases had identifiable noncompliance issues in four 
areas of “protocol violation.” They included 1) excessive start-
ing dosage (due to adjusting the AFC rating the wrong way 
once the AMH level was factored); 2) incorrect elevation of 
dosage (due to increasing more than 12.5 IU when hormonal 
or ultrasound monitoring indicated a need for elevation); 3) 
inappropriate trigger when E2 .10,000 pmol/L or follicle 
number $12 (usually because a flare cycle had prevented use 
of a GnRHa trigger); and finally, 4) wrong use of HCG during 
the luteal phase (sometimes a patient from a remote location 
self-administering Ovidrel prior to receiving approval from 
the clinic during IMP). Each time the OHSS was exacerbated 
by superimposed pregnancy (so-called late onset OHSS in all 
nine cases).
The cancellation rate before TVOA was 6.2% and 
included all cancellations after starting rFSH stimulation 
(ie, initiated cycle). However, from 173 patients (Figure 3) 
who received low rFSH (#75 IU), only 15 (8.7%) patient 
cycles were cancelled. Most cancellations were a result 
from inadequate responses in the group of younger patients 
receiving low rFSH dosage.
As part of the Australia-wide drive to decrease the twin 
rate, there was an increasing rise in the transfer of single 
embryos during the study period, being 78.4% of all transfers 
with some variation among the age groups. Younger patients 
(,30 years) had a mean of 1.1 embryos transferred and the 
mean increased in the elder age groups to a maximum of 
1.5 embryos in the group of 40–44 years. The overall mean 
(± standard deviation) number of embryos transferred with 
the PIVET algorithms was 1.28±0.45.
The mean number of oocytes collected through the 
study period was 8.7 (±5.7) oocytes and was 10.0 (±5.6) for 
those ,40 years (Table 2). Women aged under 30 years had 
11±6.2 oocytes recovered, while women 40–44 years had lower 
but acceptable oocyte numbers (mean of 6), and those with 
the poorest prognosis with age .45 years had a mean of four 
oocytes recovered. When the oocyte distribution was examined 
in relation to the AFC categories (Table 3), the highest AFC 
ratings showed a mean number of 12 oocytes, despite the 
very low rFSH starting doses. With respect to BMI groupings 
shown in Figure 3, the mean number of oocytes recovered was 
equivalent among different BMI groups, ranging from 7.4±5.9 
in the lowest BMI group (,18 kg/m2) to 8.6±5.4 in a higher 
BMI group (18–19 kg/m2), but these minimal differences 
across the other BMI groups were not significant.
Table 1 Patient demographics and treatment flow for women 
initiating rFsh stimulation under PiVeT algorithms
Cycle information (01/04/2008 to 30/04/2014)
cycles initiated, n 2,822
TVOa, n 2,646
cancellation before oocyte retrieval, n (%) 176 (6.2)
no of embryo transfer, n (% of retrievals) 2,211 (83.6)
single embryo transfer, n (% of embryo transfers) 1,588 (71.8)
increased monitoring program, n (% of retrievals) 483 (18.3)
cases admitted to hospital, n (% of started cycle) 31 (1.1)
Paracentesis, n (% severe Ohss) 9 (0.3)
Freeze all for Ohss (% of retrievals) 55 (2.1)
Age groups
,30 years, n (%) 324 (11.5)
30–34 years, n (%) 704 (24.9)
35–39 years, n (%) 952 (33.7)
40–44 years, n (%) 758 (26.9)
$45 years, n (%) 84 (3.0)
Mean age (±sD), years 36.16 (±5.27)
Stimulation protocols
antagonist, n (%) 1,619 (57.4)
Flare agonist, n (%) 850 (30.1)
aaceP, n (%) 204 (7.2)
long agonist, n (%) 107 (3.8)
Variants, n (%) 42 (1.5)
Abbreviations: aaceP, agonist antagonist conversion with estrogen priming; 
Ohss, ovarian hyperstimulation syndrome; sD, standard deviation; TVOa, 
transvaginal oocyte aspiration.
Table 2 Oocytes recovered and embryo/oocyte utilization rates for all women having a TVOa procedure categorized by age groups
Age group
,30 years 30–34 years 35–39 years 40–44 years $45 years
Mean oocytes retrieved (±sD) 11.02 (±6.21) 10.20 (±5.93) 9.10 (±5.48) 6.18 (±4.38) 4.07 (±4.11)
Oocyte utilization rate (%) 27.8 29.5 28.3 31.2 35.0
embryo utilization rate (%) 50.3 50.4 49.8 60.5 64.7





































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1




PiVeT rFsh dosing algorithms for iVF
Table 4 shows the pregnancy outcomes categorized 
according to different age groups. The data show an expected 
decreasing pregnancy and live birth rate per ET with increas-
ing age groups, from 43.4% and 36.4% in the young group, 
respectively, decreasing to 11.7% and 7.5% in the group of 
40–44 years, respectively. Some women treated toward the 
end of study period will not yet have had spare embryos 
returned in a FET cycle; however, the live birth productivity 
rate in the young group (,30 years) was as high as 57.1% per 
initiated cycle and 60.1% per TVOA (data not shown).
From Figure 3, it can be seen that 513 women (18.2% 
of total) had starting doses ,125 IU, and approximately 
half of these patients did not require any increase in dosage 
(Figure 4). Even for those starting at #75 IU, one-third had 
no change in dosage. The overall percentage of patients 
continuing at their starting dosage was 79.1% during the 
entire study period, which demonstrated the accuracy of the 
combined application of both the algorithms. Examining 
the data for dosages outside the conventional range of 
150–225 IU rFSH, 667 (23.7%) received ,150 IU; while 
1,343 (47.6%) received .300 IU. This means that less than 
one-third of women (29.7%) received conventional dosages 
of rFSH during the study period using the PIVET algorithms, 
and consequently the vast majority of patients received a 
“milder” form of stimulation.
It was observed that half of the patients had from 6–10 and 
11–15 oocytes retrieved (~32% and 22%, respectively), with 
Table 3 Oocytes recovered for all women having a TVOa 
procedure categorized according to aFc rating
AFC group Mean oocytes  
retrieved (±SD)
a++ ($40 follicles) 12.35 (±6.85)
a+ (30–39 follicles) 11.82 (±5.85)
a (20–29 follicles) 12.26 (±6.16)
B (13–19 follicles) 9.98 (±4.62)
c (9–12 follicles) 8.33 (±4.41)
D (5–8 follicles) 5.32 (±3.70)
e (,4 follicles) 4.90 (±4.53)
Abbreviations: aFc, antral follicle count; sD, standard deviation; TVOa, trans-
vaginal oocyte aspiration.
Table 4 clinical pregnancy and live birth outcomes for all women having a TVOa procedure and categorized according to age group
Age group
,30 years 30–34 years 35–39 years 40–44 years $45 years
clinical pregnancy rate per embryo transfer (%) 43.4 39.9 28.6 11.7 0.0
live birth rate per embryo transfer (%) 36.4 33.5 22.4 7.5 0.0
live birth rate per initiated cycle (%) 29 27.7 18 5.5 0.0
Freezing rate per initiated cycle (%) 64.2 64.6 51.3 28.4 9.5
live birth productivity rate, per initiated cycle (%) 57.1 51.7 33.2 8.4 0.0
Abbreviation: TVOa, transvaginal oocyte aspiration.
the greatest distribution being in the 1–5 and 6–10 oocyte 
collection groups (Figure 5). The main contribution to the 
first group (low oocyte numbers) came from older women. 
Very few women had 16–20 oocytes recovered (7.6%), and 
an absolute minimum of cases had .20 oocytes recovered 
(4.0%). Most of the latter cases were attributed to noncompli-
ance with dosing strategy. The number of women with .15 
oocytes collected at PIVET was 328/2,822 (11.6%).
Although not the main objective of the study, a direct 
comparison of the two rFSH products and consequently the 
two algorithms for the main outcome measures – efficacy 
(oocyte and embryo utilization rates and pregnancy and live 
birth rates) as well as safety (proportion of cases with .15 
oocytes and OHSS cases) was performed and showed some 
significant differences (Tables S1–S3). Overall, the data 
demonstrated that the Puregon group were slightly but sig-
nificantly older (mean of 0.5 years) with a slightly greater 
BMI (0.5 kg/m2) (Table S1). While there were significantly 
more oocytes and two pronuclei embryos retrieved for the 
Gonal-f group, there were no significant differences in rela-
tion to clinical outcomes such as pregnancy, live births, 
and miscarriage rates (Table S1). When younger women 
(,40 years) with lower AMH (,25 pmol/L) were analyzed, 
only the numbers of oocytes retrieved and two pronuclei 
embryos were significantly altered, whereas all other clini-
cal outcomes and oocyte and embryo utilization rates were 
similar (Table S2). Finally, we investigated the impact of 
the different rFSH products on the outcomes in the two 
main treatment regimens, antagonist and flare agonist cycles 
(Table S3). No significant difference was observed in the flare 
cycles, and clinical outcomes (pregnancy, live births, and 
miscarriage rates) were not altered in the antagonist group. 
However, in the latter group, the patients receiving Puregon 
were significantly older and heavier and had a lower oocyte 
yield and embryo utilization (Table S3). 
Discussion
PIVET is developing unique algorithms to assist clinicians to 
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Figure 5 The distribution of oocytes recovered, indicating that almost 90% of 
women had fewer than 16 oocytes and under 4% had more than 20 recovered; 
most resulting from breaches of the described protocols.
Figure 4 The proportion of patients in each rFsh starting dose category, who 
responded adequately to the starting dose of Fsh and required no adjustment 
(elevation) to achieve at least four follicles (for the high aFc groups) and eight to 
twelve follicles for the remainder.
Note: Where adjustments were made, this was mostly one or occasionally two 
dose increments.
Abbreviations: aFc, antral follicle count; rFsh, recombinant follicle stimulating 
hormone.
modern trends of milder stimulation, while maintaining high 
pregnancy rates, but minimizing or even completely remov-
ing the risk of OHSS. Since the first PIVET algorithm was 
published,5 the assisted reproductive technology (ART) world 
has continued to evolve with several new trends, including the 
complete removal of OHSS risk by administering antagonist 
stimulation with GnRH agonist trigger and freeze-all proce-
dures. In addition, there is a strong push, led by Australia and 
New Zealand,15 to commit to an elective single ET policy. 
Along with that concept, the idea of blastocyst culture with 
a better embryo selection policy has developed and goes 
hand-in-glove with the emergent idea of advanced genetic 
screening of embryos.16,17 Consequently, the pregnancy and 
live birth productivity rates show persisting high levels, in 
keeping with the oocyte retrieval numbers.6 Although it has 
been shown that 15 oocytes collected per TVOA may be the 
optimal number for the highest pregnancy and live birth rates 
from fresh ETs18,19 as well as for pregnancy and live birth 
productivity rates,6 the risks for severe OHSS rise drastically 
after the collection of twelve or more oocytes. Furthermore, 
attempts to schedule for 12–15 oocytes retrieval means that 
many cases will unintentionally result in $20 oocytes col-
lected and an exponential rise in OHSS risk. Here, using the 
PIVET algorithms, only 4% of cases returned 20 or more 
oocytes recovered, but these were due to specific protocol 
violations. The proportion of women with .15 oocytes 
retrieved per egg collection was 11.6%. This was signifi-
cantly lower than those receiving conventional rFSH dosages 
(112.5–300 IU) recently reported20 (38.2%) (P,0.0001) and 
demonstrated our milder stimulation.
During the entire study period, OHSS prevention has 
been the main focus, and other preventive initiatives were 
also undertaken, including the management of more cycles 
by an antagonist regimen, which provided the clinician 
with an opportunity to trigger with a GnRH-agonist and 
decrease the risk of OHSS.21 Furthermore, patients were 
offered increased monitoring to ensure all patients with 
OHSS symptoms were detected at the earliest possible stage 
and that relevant expedient steps could be implemented, 
such as intravenous fluids to counteract hypovolemia, 
which were often enough to prevent the complete disorder 
from developing. The high number of patients on increased 
monitoring did not necessarily reflect many patients at risk 
of developing OHSS, but only as a relevant service to detect 
all cases and expedite early management. In addition, the 
freeze-all strategy to prevent OHSS in high-risk scenarios22 
was used throughout the study period. However, despite 
various preventive strategies, OHSS cases were encoun-
tered during the study (0.3%), but each and every case 
was shown retrospectively to be related to noncompliance 
with the PIVET protocols and regimens as defined in the 
methodology section. All the cases of severe OHSS were 
late onset, associated with pregnancy, but also had one of 
four identifiable noncompliance issues with the advised 
procedure as defined earlier. We are aware of the contro-
versy over the use of HCG as luteal support, but have data 
supporting its use to improve the chance of pregnancy23 
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PiVeT rFsh dosing algorithms for iVF
Its use is clearly safe in women with lower AFC and AMH 
levels, for example, categories C, D, and E of the algo-
rithms; perhaps further restrictions need to be considered 
for the A groups as well as some group B cases. We have 
now adjusted the protocols to avoid luteal phase HCG in all 
cases with either AFC rating $15 antral follicles or AMH 
levels $15pmol/L, in addition to the existing restriction of 
recovery of $12 oocytes at TVOA.
High cancellation rates prior to oocyte retrieval can be 
explained by insufficient follicle development as a result of 
an inappropriately low rFSH starting dose. In our study, the 
cancellation rate before TVOA was 6.2% and included all 
cancellations after starting rFSH stimulation (ie, initiated 
cycles). This compared favorably with the overall cancel-
lation rate of 24 of 161 cases (14.9%) in the CONSORT 
algorithm (P,0.001).4 Furthermore, in our study, only 15 
of 173 (8.7%) patients were cancelled in the low FSH group 
(#75 IU), and this was significantly lower than the 25% 
(four of twelve cases) cancellation rate for the CONSORT 
algorithm, in a potentially good-responder group, requiring 
low rFSH.4 Most cancellations in both series occurred from 
inadequate responses in the group of younger patients receiv-
ing low rFSH dosage. 
Moreover, young patients with high AFC/AMH often 
expressed disappointment as they were part of the distribution 
grouping of one to five oocytes. However, their pregnancy 
rates were actually high, in keeping with our earlier published 
data that ,5 oocytes from younger high-responders gener-
ate embryos that have a higher implantation rate than those 
from higher order oocyte collections.6 While those ,30 years 
and patients 40–44 years had a mean number of 1.1 and 1.5 
embryos transferred, respectively, the overall mean was 
1.28±0.45, which was significantly lower (P,0.001) than 
that demonstrated in another study (1.94±0.24), which was 
also described as an “optimum oocyte retrieval and transfer 
strategy.”20 Furthermore, we noted a trend toward higher 
embryo utilization rates over oocyte utilization rates in all 
cases, but both of these rates were increased in older patients. 
The higher embryo utilization rate reflects the higher number 
of usable, mature, and fertilizable M-II eggs and is a use-
ful index signifying the proportion of eggs that are actually 
mature. However, the higher rates in older women may reflect 
the request by older women to undertake an ET despite lower 
graded embryos.
Overall both the dosing algorithms, adjusted for ~8.3 or 
12.5 IU increments, have proven effective in meeting the 
aims of collecting eight to twelve oocytes from the majority 
of women undergoing ovarian stimulation for IVF proce-
dures. Specifically, the average number of oocytes collected 
for Gonal-f and Puregon was 9.1 and 8.3, respectively, and 
10.1 and 8.0, respectively, for younger women (,40 years) 
with lower AMH. Although in the overall data set, women 
receiving Puregon were slightly but significantly older 
(0.5 years), the reduced oocyte retrieval using Puregon was 
probably more related to the lower dosage derived from the 
algorithm, as in the younger group with no significant differ-
ence in mean age, the reduced trend in oocyte retrieval was 
also observed. Additionally, the approximate 8.3 IU subdoses 
of Puregon are not guaranteed by the manufacturer and could 
also play a role in these observed differences. Importantly, 
there was no significant difference in clinical pregnancy, live 
births, and miscarriage rates between the two rFSH products 
for all patients collectively or in a subset of younger women 
(,40 years). 
In relation to the impact of specific rFSH stimulation 
protocols, we did not observe any influence of the rFSH 
product in flare agonist stimulation, while clinical parameters 
(pregnancy/livebirths/miscarriage) were also not altered 
in the antagonist stimulation. However, similar to above, 
oocyte retrievals were significantly enhanced in the Gonal-f 
group. The cause of this increase is not known at present 
but is again probably related to the higher concentrations 
of Gonal-f used.
Interestingly, the number of cases with .15 oocytes 
was kept at a low of 11.4% using both of the algorithms, 
significantly fewer compared to 38.2% in another recent 
study20 and very few patients exceeded 20 or more oocytes in 
our study. This is comparable with modern trends of milder 
stimulation with a view of absolute minimization of the risk 
of OHSS, with patient safety being of paramount importance. 
It is our view that such risk can be reduced under 0.01%, but 
this will require a more determined clinical approach, with 
stronger adherence to the protocols described here, along 
with appropriately restricted use of HCG for triggering in 
tandem with its careful use in the luteal phase.
Finally, although PIVET has published data showing 
excellent pregnancy rates from FET cycles, particularly where 
these are undertaken under hormone replacement therapy 
control,24 we are not supportive of the view that fresh ETs 
should be avoided.22 We believe that the application of the 
PIVET algorithms provides a rational approach enabling fresh 
and frozen ETs leading to optimal pregnancy productivity 
rates, along with the potentially complete avoidance of severe 
OHSS cases, all being derived from the same TVOA.
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PIVET Medical Centre is accredited with both the Australian 
Reproductive Technology Committee (RTAC) and the Repro-
ductive Technology Council (RTC) of Western Australia that 
functions under statutory regulation. Both the authorities con-
duct annual accreditation reviews for licencing of ART clinics, 
with a focus on multiple pregnancies and OHSS rates being of 
concern if elevated beyond currently adjusted standards.
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PiVeT rFsh dosing algorithms for iVF
Table S3 clinical outcomes for all patients undergoing rFsh stimulation using either gonal-f or Puregon and analyzed according to 
treatment cycle type
Antagonist cycles Flare agonist cycles
Gonal-f (±SD) Puregon (±SD) Gonal-f (±SD) Puregon (±SD)
Mean age (years) 34.3 (±4.8) 35.2 (±5.4)** 37.7 (±4.5) 37.7 (±4.9)ns
Mean BMi (kg/m2) 24.6 (±4.6) 25.0 (±4.6)**** 24.2 (±4.2) 24.8 (±4.3)ns
Mean eggs collected 10.4 (±5.8) 9.4 (±5.6)** 7.2 (±4.6) 7.1 (±5.3)ns
Mean 2Pn generated 6.0 (±4.2) 5.3 (±4.0)** 3.9 (±3.2) 3.8 (±3.6)ns
Mean oocyte utilization (%) 30.5 (±20.6) 33.1 (±21.9)ns 35.5 (±24.6) 34.1 (±26.2)ns
Mean embryo utilization (%) 50.7 (±29.6) 56.4 (±31.8)** 60.7 (±34.1) 59.7 (±43.2)ns
clinical pregnancy rate per fresh eT (%) 32.8 30.5ns 22.7 25.7ns
live birth rate per fresh eT (%) 26.2 24.7ns 19.2 19.7ns
Miscarriage rate per pregnancy (%) 20.0 19.0ns 15.4 23.2ns
Notes: No significant differences were observed for all parameters using the flare agonist stimulation regimen. For antagonist cycles, the populations were slightly but 
significantly different in terms of mean age, mean BMI, number of oocytes, and embryos with 2PN retrieved and the embryo utilization rate. However, pregnancy, birth, and 
miscarriage rates between the two rFSH agents for antagonist cycles were not significantly different. Asterisk indicates significant difference between rFSH drugs in the same 
cycle type. NS indicates no significant difference between rFSH drugs in the same cycle type.
Abbreviations: 2Pn, two pronuclei; BMi, body mass index; eT, embryo transfer; rFsh, recombinant follicle stimulating hormone; sD, standard deviation.
Table S1 clinical outcomes for all patients undergoing rFsh stimulation using either gonal-f or Puregon
Gonal-f (±SD) Puregon (±SD) P-value
Mean age (years) 35.9 (±5.2) 36.4 (±5.4) 0.012*
Mean BMi (kg/m2) 24.4 (±4.4) 24.9 (±4.5) 0.003**
Mean eggs collected 9.1 (±5.7) 8.3 (±5.7) 0.0003***
Mean 2Pn generated 5.1 (±4.0) 4.7 (±3.9) 0.009**
Mean oocyte utilization (%) 33.3 (±23.6) 34.0 (±24.3) 0.453
Mean embryo utilization (%) 55.3 (±32.4) 57.8 (±36.7) 0.063
clinical pregnancy rate per fresh eT (%) 28.2 28.4 0.945
live birth rate per fresh eT (%) 22.8 22.4 0.838
Miscarriage rate per pregnancy (%) 19.0 21.2 0.551
Notes: No significant differences were observed for pregnancy, birth, or miscarriage rates. However, the populations were slightly but significantly different in terms of mean 
age, mean BMi, and the number of oocytes and embryos with 2Pn retrieved. *P,0.05, **P,0.01, ***P,0.001.
Abbreviations: 2Pn, two pronuclei; BMi, body mass index; eT, embryo transfer; rFsh, recombinant follicle stimulating hormone; sD, standard deviation.
Supplementary materials
Table S2 clinical outcomes in younger women (,40 years), with aMh values ,25 pmol/l, receiving rFsh stimulation using either 
gonal-f or Puregon
Gonal-f (±SD) Puregon (±SD) P-value
Mean age (years) 34.1 (±4.0) 34.6 (±3.7) 0.115
Mean BMi (kg/m2) 24.7 (±4.5) 25.2 (±4.9) 0.196
Mean eggs collected 10.1 (±5.4) 8.0 (±5.1) ,0.0001****
Mean 2Pn generated 5.7 (±4.0) 4.6 (±3.7) 0.0007***
Mean oocyte utilization (%) 30.1 (±21.5) 31.8 (±22.6) 0.357
Mean embryo utilization (%) 50.1 (±29.8) 53.6 (±36.1) 0.204
clinical pregnancy rate per fresh eT (%) 32.8 34.9 0.693
live birth rate per fresh eT (%) 27.1 28.4 0.815
Miscarriage rate per pregnancy (%) 17.4 18.5 0.984
Note: Only significant differences between number of oocytes collected and number of embryos with 2PN were observed. ***P,0.001, ****P,0.0001.
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